Thursday, July 25, 2024
HomeFunding OK-based Biotechnology Company Cadenza Bio Secures $2.44M in Series Seed Funding

[Funding alert] OK-based Biotechnology Company Cadenza Bio Secures $2.44M in Series Seed Funding

OK-based biotechnology company Cadenza Bio secures $2.44M in series seed funding. Plains Ventures led the financing, with participation from the Oklahoma Life Science Fund, Cortado Ventures, Boyd Street Ventures, and Illinois Ventures.

OK-based biotechnology company Cadenza Bio secures $2.44M in series seed funding. Plains Ventures led the financing, with participation from the Oklahoma Life Science Fund, Cortado Ventures, Boyd Street Ventures, and Illinois Ventures.

The financing supports non-clinical safety and toxicology studies to advance Cadenza’s lead development candidate, CAD-1, for treatment of Multiple Sclerosis (MS), and additionally provides funds to develop secondary indication(s).

Read also – Canada-based Friendlier Secures $5M in Funding

MS is a potentially debilitating disease where the immune system attacks and removes the protective myelin layer covering on nerve fibers in the brain and spinal cord, thereby inhibiting communication between the brain and the body and also causing nerve loss.

Plains Ventures President and Managing Director, Justin Wilson said, “We proudly support Cadenza’s efforts to dramatically improve the lives of patients suffering from demyelinating disease. Our conviction in Cadenza is multifaceted; CAD-1 is an elegant solution to a primary market need, there are strong opportunities for secondary indications in the future, and the company has assembled an extraordinary team of women to lead the way,”.

Dr. Carol Curtis, Chief Executive Officer of Cadenza Bio said, “My co-founder Dr. Elaine Hamm and I are thrilled to have this strong syndicate of early investors supporting Cadenza’s drug development program, Our goal goes beyond incremental improvements. We are dedicated to breaking the cycle of disease and, in doing so, transforming lives. We aim not only to alleviate symptoms but to halt progression, promote repair and restore quality of life to enable full activity, empowering patients to regain control over their health.”

About Cadenza Bio, Inc.

Cadenza Bio, Inc. was founded in 2022 to accelerate and support the development of a series of novel, and highly selective Estrogen Receptor β (ERβ) targeting small-molecule compounds. They are dedicated to advancing therapeutic drugs that will make a meaningful impact in the lives of patients suffering from debilitating diseases.

Read also – FL-based SellersFi Secures Funding of Undisclosed Amount

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular